PRKDC and renal cell carcinoma: Silencing of PDIA6-induced decreases in p-DNA-PK and Rad51 was restored by over-expression of FZD1, suggesting that PDIA6 might contribute to the resistance of renal cell carcinoma to imatinib through activation of Wnt3a/FZD1 pathway.